180 related articles for article (PubMed ID: 32236605)
1. CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells.
Zamagni A; Pasini A; Pirini F; Ravaioli S; Giordano E; Tesei A; Calistri D; Ulivi P; Fabbri F; Foca F; Delmonte A; Molinari C
Int J Oncol; 2020 Jun; 56(6):1574-1584. PubMed ID: 32236605
[TBL] [Abstract][Full Text] [Related]
2. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
[TBL] [Abstract][Full Text] [Related]
3. Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS‑mutated lung cancer cells.
Wang M; Chen X; Fu G; Ge M
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36222298
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatin‑resistant non‑small cell lung cancer.
Zhao J; Xue X; Fu W; Dai L; Jiang Z; Zhong S; Deng B; Yin J
Int J Oncol; 2020 May; 56(5):1083-1092. PubMed ID: 32319573
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
6. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
7. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
9. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
[TBL] [Abstract][Full Text] [Related]
10. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
11. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
12. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.
Pan C; Duan H; Wu Y; Zhu C; Yi C; Duan Y; Lu D; Guo C; Wu D; Wang Y; Fu X; Xu J; Chen Y; Luo M; Tian W; Pan T; Xu W; Zhang S; Huang J
Int J Oncol; 2020 Oct; 57(4):939-955. PubMed ID: 32945394
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
15. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Wang H; Fei Z; Jiang H
J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
[TBL] [Abstract][Full Text] [Related]
16. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
17. Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.
Sun Y; Bao X; Ren Y; Jia L; Zou S; Han J; Zhao M; Han M; Li H; Hua Q; Fang Y; Yang J; Wu C; Chen G; Wang L
Cell Death Dis; 2019 May; 10(6):400. PubMed ID: 31127087
[TBL] [Abstract][Full Text] [Related]
18. CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells.
Yin J; Zhang H; Wu X; Zhang Y; Li J; Shen J; Zhao Y; Xiao Z; Lu L; Huang C; Zhang Z; Du F; Wu Y; Kaboli PJ; Cho CH; Yuan D; Li M
Int J Mol Med; 2020 Jun; 45(6):1783-1792. PubMed ID: 32236608
[TBL] [Abstract][Full Text] [Related]
19. let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer.
Yin J; Hu W; Pan L; Fu W; Dai L; Jiang Z; Zhang F; Zhao J
Oncol Rep; 2019 Aug; 42(2):495-508. PubMed ID: 31233201
[TBL] [Abstract][Full Text] [Related]
20. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]